Merck KGaA

Company

Last mentioned: Mar 17, 2026

Timeline

Mar 17, 2026
Commercialization Agreement

Strategic partnership signed for Eurasian market distribution and sales.
2026
Regulatory Filings

Anticipated submission of product dossiers to regional health authorities.
Q4 2025
Patent Grants

BioNxt receives official patent approvals for Cladribine ODF in Europe and Eurasia.

Stories mentioning Merck KGaA 1

BioNxt Secures Eurasian Commercialization Deal for Cladribine ODF Platform

BioNxt Solutions has finalized a strategic agreement for the commercialization of its Cladribine Oral Dissolvable Film (ODF) in Eurasia. The deal follows critical patent grants in both Europe and Eurasia, marking a transition from development to market entry for the company's Multiple Sclerosis treatment platform.

Mar 17, 2026 2 sources